Europe

Siemens raises 2022 outlook on demand for COVID-19 test

Published

3 years ago

May 4, 2022

Cecilia Odey

Medical device company Siemens Healthineers raised its full-year outlook following robust sales in its second quarter, driven by higher-than-expected demand for the company’s COVID-19 rapid antigen tests.

The German company said on Wednesday it had revised up its year-on-year revenue expectations for the fiscal year,
which would end in September.

It’s now expecting growth between 5.5 per cent and 7.5 per cent, compared to the previous 3per cent to 5 per cent.

The diagnostics segment achieved revenue growth of 37.2 per cent.

The company took in almost 680 million euros (715 million dollars) in revenue from the rapid Coronavirus tests.

It said the overall second quarter earnings before interests and taxes increased by 47 per cent over the prior-year period to 980 million euros.

Net income rose 30 per cent to 583 million euros.

Sales were only slightly impacted by Coronavirus restrictions in China and supply chain disruptions, it said.

In addition to the rapid test business, Healthineers benefited from the acquisition of the U.S. cancer specialist
varian.

Related Topics:

Up Next

Belarus to test rapid response forces in surprise military manoeuvre

Don't Miss

U.S. Supreme Court potential shock move on abortion sends protesters onto Washington streets

Cecilia Odey

NEWSVERGE, published by The Verge Communications is an online community of international news portal and social advocates dedicated to bringing you commentaries, features, news reports from a Nigerian-African perspective. A unique organization, founded in the spirit of Article 19 of the Universal Declaration of Human Rights, comprising of ordinary people with an overriding commitment to seeking the truth and publishing it without fear or favour. The Verge Communications is fully registered with the Corporate Affairs Commission of the Federal Republic of Nigeria as a corporate organization.